Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Jounce Therapeutics, Inc. (JNCE) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/04/2023 8-K Quarterly results
03/27/2023 8-K Acquisition/merger/asset purchase announced
Docs: "AGREEMENT AND PLAN OF MERGER",
"NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH"
03/15/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences"
03/13/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
02/23/2023 8-K Entry into a Material Definitive Agreement, Cost Associated with Exit or Disposal Activities, Unregistered Sales of Equity Se...
Docs: "RECOMMENDED BUSINESS COMBINATION OF",
"REDX PHARMA PLC CO-OPERATION AGREEMENT",
"AGREEMENT AND PLAN OF MERGER",
"Amendment No. 1 to Employment Agreement",
"Amendment No. 1 to Amended and Restated Employment Agreement",
"Amendment No. 1 to Amended and Restated Employment Agreement",
"Amendment No. 1 to Amended and Restated Employment Agreement",
"CONSULTING AGREEMENT",
"CONSULTING AGREEMENT",
"CONSULTING AGREEMENT"
01/20/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/05/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
12/27/2022 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "ASSET PURCHASE AND LICENSE AMENDMENT AGREEMENT",
"GILEAD TO ACQUIRE ALL REMAINING RIGHTS TO POTENTIAL FIRST-IN-CLASS IMMUNOTHERAPY GS-1811 FROM JOUNCE THERAPEUTICS"
12/20/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
Docs: "Jounce Therapeutics Reports Third Quarter 2022 Financial Results - INNATE trial of JTX-8064 +/- pimivalimab Phase 1 Dose Escalation data at ESMO-IO Annual Congress -"
08/30/2022 8-K Investor presentation
Docs: "A NEXT GEN IMMUNOTHERAPY COMPANY AUGUST 2022",
"Jounce Therapeutics Reports Results from Phase 2 Randomized SELECT Trial Testing 2 Different Doses of Vopratelimab in TISvopra Biomarker-Selected Patients - SELECT trial of vopratelimab in combination with pimivalimab versus pimivalimab alone did not meet its primary endpoint of mean tumor change averaged over 9 and 18 weeks -"
08/04/2022 8-K Quarterly results
Docs: "Jounce Therapeutics Reports Second Quarter 2022 Financial Results - INNATE trial of JTX-8064 +/- pimivalimab on track to present preliminary data on at least 80 Phase 2 patients across multiple cohorts by year end -"
06/27/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/07/2022 8-K Quarterly results
03/02/2022 8-K Quarterly results
01/10/2022 8-K Investor presentation
Docs: "A NEXT GEN IMMUNOTHERAPY COMPANY JANUARY 2022"
11/04/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "JOUNCE THERAPEUTICS, INC. $75,000,000",
"Prospectus Supplement to Registration Statement on Form S-3"
11/04/2021 8-K Quarterly results
Docs: "Jounce Therapeutics Reports Third Quarter 2021 Financial Results - Commenced enrollment in tumor-specific monotherapy and pimivalimab combination expansion cohorts of INNATE trial of JTX-8064 -"
09/15/2021 8-K Quarterly results
08/05/2021 8-K Quarterly results
Docs: "Jounce Therapeutics Reports Second Quarter 2021 Financial Results - INNATE monotherapy dose escalation enrollment completed and target dose selected, on track to initiate indication specific expansions in third quarter 2021-"
06/23/2021 8-K Quarterly results
05/04/2021 8-K Quarterly results
03/10/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
02/12/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
11/06/2020 8-K Quarterly results
Docs: "Jounce Therapeutics Reports Third Quarter 2020 Financial Results -On track to begin enrollment in the Phase 1 trial for JTX-8064 by year-end 2020- -Established exclusive license agreement with Gilead for JTX-1811-"
11/02/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Jounce Therapeutics Announces Update on Vopratelimab Program - No further enrollment in EMERGE trial of vopratelimab in combination with ipilimumab based on interim analysis-"
09/01/2020 8-K Quarterly results
08/07/2020 8-K Quarterly results
06/29/2020 8-K Quarterly results
06/04/2020 8-K Entry into a Material Definitive Agreement
05/06/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy